Document Detail

Aclidinium: in chronic obstructive pulmonary disease.
MedLine Citation:
PMID:  23046206     Owner:  NLM     Status:  In-Data-Review    
Aclidinium, an inhaled, long-acting antimuscarinic agent, has been developed as a twice-daily maintenance treatment for chronic obstructive pulmonary disease (COPD). Treatment with the approved dosage of aclidinium (400 μg twice daily) statistically significantly improved bronchodilation, disease-specific health status, dyspnoea, night-time COPD symptoms and use of rescue medication compared with placebo in pivotal studies of 12 (ACCORD COPD I) or 24 (ATTAIN) weeks duration in patients with moderate to severe COPD. The improvements in bronchodilation, health status and dyspnoea were clinically meaningful compared with placebo after 24 weeks of treatment in ATTAIN; generally similar results were seen after 12 weeks of treatment in both trials. Aclidinium also statistically significantly reduced the incidence of COPD exacerbations compared with placebo in these studies (albeit neither trial was designed to assess exacerbation frequency). Inhaled aclidinium has a low systemic bioavailability; the approved dosage was generally well tolerated in clinical trials of up to 52 weeks duration. Aclidinium had an adverse event profile that was similar to that of placebo and characterized by low incidences of major adverse cardiovascular events and potential anticholinergic adverse events.
James E Frampton
Related Documents :
18536066 - Effects of warm-supplementing kidney yang (wsky) capsule added on risperidone on cognit...
9892856 - Amisulpride versus amineptine and placebo for the treatment of dysthymia.
12590356 - Changes in cognitive functioning with risperidone and olanzapine treatment: a large-sca...
15705006 - Effects of behavioral therapy on weight loss in overweight and obese patients with schi...
24455046 - A clinical study of the effect of calcium sodium phosphosilicate on dentin hypersensiti...
23244366 - Sudden gains in cognitive therapy and interpersonal therapy for social anxiety disorder.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Drugs     Volume:  72     ISSN:  0012-6667     ISO Abbreviation:  Drugs     Publication Date:  2012 Oct 
Date Detail:
Created Date:  2012-10-10     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7600076     Medline TA:  Drugs     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  1999-2011     Citation Subset:  IM    
Adis, Auckland, New Zealand.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Interactions of DPPC with semitelechelic poly(glycerol methacrylate)s with perfluoroalkyl endgroups.
Next Document:  Multivariate mixed linear model analysis of longitudinal data: an information-rich statistical techn...